Objectives: Our objective was to pilot test an electronic health record-embedded decision support tool to facilitate prostate-specific antigen (PSA) screening discussions in the primary care setting.
Methods: We pilot-tested a novel decision support tool that was used by 10 primary care physicians (PCPs) for 6 months, followed by a survey. The tool comprised (1) a risk-stratified algorithm, (2) a tool for facilitating shared decision-making (Simple Schema), (3) three best practice advisories (BPAs: <45, 45-75, and >75 years), and (4) a health maintenance module for scheduling automated reminders about PSA rescreening.
Results: All PCPs found the tool feasible, acceptable, and clear to use. Eight out of ten PCPs reported that the tool made PSA screening conversations somewhat or much easier. Before using the tool, 70% of PCPs felt confident in their ability to discuss PSA screening with their patient, and this improved to 100% after the tool was used by PCPs for 6 months. PCPs found the BPAs for eligible (45-75 years) and older men (>75 years) more useful than the BPA for younger men (<45 years). Among the 10 PCPs, 60% found the Simple Schema to be very useful, and 50% found the health maintenance module to be extremely or very useful. Most PCPs reported the components of the tool to be at least somewhat useful, with 10% finding them to be very burdensome.
Conclusion: We demonstrated the feasibility and acceptability of the tool, which is notable given the marked low acceptance of existing tools. All PCPs reported that they would consider continuing to use the tool in their clinic and were likely or very likely to recommend the tool to a colleague.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11006556 | PMC |
http://dx.doi.org/10.1055/s-0044-1780511 | DOI Listing |
Womens Health (Lond)
January 2025
Global Health, and Department Pediatrics, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Background: Empowerment is vital for individuals' control over their lives but is often constrained for women in India due to deep-rooted patriarchal norms. This affects health, and resource distribution, and increases domestic violence. Domestic violence including physical, sexual, emotional, economic, and psychological abuse is a significant human rights and public health issue.
View Article and Find Full Text PDFClin Trials
January 2025
Department of Biostatistics, University of Washington, Seattle, WA, USA.
Background: N-of-1 trials compare two or more treatment options for a single participant. These trials have been used to study options for chronic conditions such as arthritis and attention deficit hyperactivity disorder. In addition, they have been suggested as a means to study interventions in rare populations that may not be tractable to include in standard clinical trials, such as treatment options for HIV-positive patients in need of organ transplant.
View Article and Find Full Text PDFClin Trials
January 2025
Central Monitoring and Data Analytics, GSK, Brentford, UK.
Background: Clinical trials handle a huge amount of data which can be used during the trial to improve the ongoing study conduct. It is suggested by regulators to implement the remote approach to evaluate clinical trials by analysing collected data. Central statistical monitoring helps to achieve that by employing quantitative methods, the results of which are a basis for decision-making on quality issues.
View Article and Find Full Text PDFEur J Breast Health
January 2025
Department of Biomedical Engineering, Yeditepe University Faculty of Engineering, İstanbul, Turkey.
Objective: To investigate integrating an artificial intelligence (AI) system into diagnostic breast ultrasound (US) for improved performance.
Materials And Methods: Seventy suspicious breast mass lesions (53 malignant and 17 benign) from seventy women who underwent diagnostic breast US complemented with shear wave elastography, US-guided core needle biopsy and verified histopathology were enrolled. Two radiologists, one with 15 years of experience and the other with one year of experience, evaluated the images for breast imaging-reporting and data system (BI-RADS) scoring.
Ann Pharmacother
January 2025
ForHealth Consulting, UMass Chan Medical School, Shrewsbury, MA, USA.
Objective: The objective was to describe the pharmacology, efficacy, safety, and recommendations for the use of newly approved preventive agents and vaccines for respiratory syncytial virus (RSV) and discuss their uptake during the 2023 to 2024 RSV season.
Data Sources: A literature search of PubMed was performed (January 2020 to February 2024) with the search terms RSV vaccine, preventive antibody, and RSV prevention. Utilization data were collected from TriNetX using the US Collaborative Network (May 2024) using the terms palivizumab, nirsevimab, and RSV prefusion F protein.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!